In this sense, our results showed a tendency to decrease GSK3β activity in samples with significant overexpression of PrPC (both with WB and RT-PCR, from Braak stages I–II) in contrast to a progressive increase in GSK3β activity in advanced AD stages that reverse correlated with the progressive decrease of PrPC levels. Here, GSK3B is linked to Alzheimer disease.